Clinical trials: Nausea
Chemotherapy-induced Nausea and Vomiting
To Study the Safety and Effectiveness of a Granisetron Patch to Treat Chemotherapy-Induced Nausea and Vomiting (CINV)
To study the safety and effectiveness of a granisetron patch to treat Chemotherapy-Induced Nausea and Vomiting (CINV)
- Trial name
- NCT00273468
- Testing
- Granisetron
- Volunteers
- 630 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Postoperative Nausea and Vomiting
2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)
The purpose of this study is to assess the safety and efficacy of 2 doses of an approved drug for a new indication in the prevention of postoperative nausea and vomiting in patients receiving general anesthesia for open abdominal…
- Trial name
- NCT00090155
- Testing
- MK0869, aprepitant, Comparator: ondansetron IV
- Volunteers
- 805 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine, Pain
A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain
A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain.
- Conditions
- Migraine, Pain, Nausea, Vomiting
- Trial name
- NCT03877718
- Testing
- Arm 1: CL-H1T, Arm 2: CL-H1T, Arm 3: Sumatriptan Succinate 100 mg capsule
- Where
- 3 sites in United States
- Volunteers
- 475 people
- Sponsor
- Charleston Laboratories, Inc
PONV
A Comparison of the Efficacy of Amisulpride and Placebo in the Prevention of PONV in Patients at Moderate-to-high Risk of PONV.
A comparison of the efficacy of Amisulpride and placebo in the prevention of PONV in patients at moderate-to-high risk of PONV.
- Trial name
- NCT05822713
- Testing
- Amisulpride
- Volunteers
- 516 people
- Sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd.
Nausea and Vomiting, Chemotherapy-Induced
Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy
This study was designed to assess the safety and efficacy of an investigational agent administered in addition to a standard anti-emetic regimen for the treatment of chemotherapy induced nausea and vomiting.
- Trial name
- NCT00169572
- Testing
- Aprepitant, Ondansetron, GW679769
- Where
- 51 sites in Argentina, Austria and 17 more
- Volunteers
- 492 people
- Sponsor
- GlaxoSmithKline
Postoperative Nausea and Vomiting
Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients
The objective of the study is to assess the safety and efficacy of two doses of IV palonosetron each administered as a single dose for the prevention of postoperative nausea and vomiting through 72 hours postoperatively in…
- Trial name
- NCT00828295
- Testing
- palonosetron
- Where
- 13 sites in Russia, Ukraine
- Volunteers
- 150 people
- Sponsor
- Helsinn Healthcare SA
Nausea and Vomiting, Postoperative
Post Operative Nausea and Vomiting (PONV) Rescue Outcomes After Amisulpride Treatment
PROMPT (PONV Rescue Outcomes after AMisulPride Treatment) is an observational Phase IV study designed to evaluate real-world evidence in relation to the care continuum of Post Operative Nausea and Vomiting (PONV), as well as the…
- Trial name
- PROMPT (NCT04954365)
- Testing
- Rescue Post-Operative Nausea and Vomiting (PONV) treatment according to the standard of care (SOC), Amisulpride
- Sponsor
- Acacia Pharma Ltd
Nausea and Vomiting, Chemotherapy-Induced
A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
This is a Phase III trial designed to demonstrate that casopitant when added to dexamethasone and ondansetron is more effective in the prevention of vomiting then dexamethasone and ondansetron alone, in patients who receive a…
- Trial name
- NCT00431236
- Testing
- Oral Casopitant (GW679769), IV Casopitant (GW679769), IV ondansetron hydrochloride
- Where
- 80 sites in Argentina, Belgium and 20 more
- Volunteers
- 810 people
- Sponsor
- GlaxoSmithKline
Idiopathic Gastroparesis, Diabetic Gastroparesis
Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
To investigate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.
- Conditions
- Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis
- Trial name
- NCT04028492
- Testing
- Tradipitant, Open Label Tradipitant
- Where
- 36 sites in United States
- Volunteers
- 979 people
- Sponsor
- Vanda Pharmaceuticals
Chemotherapy-induced Nausea and Vomiting, Nausea Post Chemotherapy
Prevention of Unmitigated Chemotherapy-induced Emesis
Chemotherapy-induced nausea and vomiting (CINV) remains a major obstacle to patient care and continues to decrease quality of life.
- Trial name
- PUCE (NCT03996863)
- Testing
- Otoband
- Where
- United States
- Sponsor
- Otolith Labs
Migraine
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to <18 years with episodic migraine.
- Trial name
- NCT05156398
- Testing
- Rimegepant
- Where
- 93 sites in United States, Canada and 5 more
- Volunteers
- 640 people
- Sponsor
- Pfizer
Chemotherapy-induced Nausea and Vomiting
Phase II Proof-of-concept Study of APD421
Evaluation of efficacy of APD421 in preventing nausea and vomiting caused by cisplatin
- Trial name
- NCT01303978
- Testing
- APD421
- Where
- 4 sites in Denmark, United Kingdom
- Volunteers
- 51 people
- Sponsor
- Acacia Pharma Ltd
Nausea and Vomiting, Testicular Germ Cell Tumor
Lerisetron Compared With Granisetron in Preventing Nausea and Vomiting in Men Being Treated With Radiation Therapy for Stage I Seminoma
RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients treated with radiation therapy. It is not yet known whether lerisetron is more effective than granisetron in preventing nausea and…
- Trial name
- NCT00004219
- Testing
- granisetron hydrochloride, lerisetron, radiation therapy
- Volunteers
- 150 people
- Sponsor
- Simbec Research
Nausea, Vomiting
Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)
A multicenter trial to assess the safety and efficacy of an investigational drug in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with confirmed solid tumors who will be treated with a chemotherapy…
- Trial name
- NCT00090207
- Testing
- MK0869, aprepitant / Duration of Treatment: 3 days, Comparator: ondansetron / Duration of Treatment: 4 days
- Volunteers
- 477 people
- Sponsor
- Merck Sharp & Dohme LLC
Functional Dyspepsia
Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia
The study is conducted in patients with functional dyspepsia or chronic gastritis. The purpose of this study is to: assess whether the dose of Itopride Hydrochloride 150 mg extended release tablets, taken once daily has a similar…
- Trial name
- NCT06217393
- Testing
- Itopride Hydrochloride 150 mg extended release tablets, Itopride Hydrochloride 50 mg film coated tablets
- Where
- 19 sites in Armenia, Malaysia and 3 more
- Volunteers
- 564 people
- Sponsor
- Abbott
Chemotherapy-Induced Nausea and Vomiting
A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)
This study will assess the bioequivalence of single oral doses of aprepitant (MK0869) to a single intravenous infusion of fosaprepitant (MK0517) and also determine the effect of food on the bioavailability of oral aprepitant.
- Trial name
- NCT00945321
- Testing
- aprepitant 165 mg, Comparator: aprepitant 185 mg, Comparator: fosaprepitant 150 mg
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Motion Sickness
Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Safety, Efficacy and Pharmacokinetics of DPI 386 Nasal Gel for the Prevention and Treatment of Nausea Associated with Motion Sickness in Senior Subjects With…
- Trial name
- NCT03988530
- Testing
- Scopolamine
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Repurposed Therapeutics, Inc.
Nausea and Vomiting, Postoperative, Postoperative Nausea and Vomiting
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.
- Trial name
- NCT00334152
- Testing
- casopitant
- Where
- 70 sites in United States, Belgium and 9 more
- Volunteers
- 515 people
- Sponsor
- GlaxoSmithKline
Smoking Cessation, Stress
Efficacy and Tolerability of Combination Varenicline With Hydroxyzine as a Potential Smoking Cessation Treatment
This open-label study will evaluate hydroxyzine, a first-generation antihistamine, combined with varenicline, to help smokers abstain from smoking during a 12-week trial period by diminishing the nausea, stress, anxiety, and…
- Conditions
- Smoking Cessation, Stress, Sleep Disturbance, Nausea
- Trial name
- HAVE (NCT04188106)
- Testing
- Varenicline Pill, Hydroxyzine Pill
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Rose Research Center, LLC
Chemotherapy-Induced Nausea and Vomiting
Comparative Study of Palonosetron With Granisetron as a Control in Patients Receiving Highly Emetogenic Chemotherapy
To compare palonosetron with granisetron hydrochloride as a control in the efficacy of intravenous single dose in preventing acute and delayed gastro-intestinal disorders, such as nausea and vomiting induced by highly emetogenic…
- Trial name
- NCT00359567
- Testing
- palonosetron, granisetron hydrochloride
- Where
- Japan
- Volunteers
- 1,140 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.